Clinical Trial

Using FAPI PET/MRI to Evaluate Prostate Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to gain more information about how FAPI (fibroblast activation protein inhibitor) binds to certain type of cells in the tumor tissue. The main question it aims to answer is how this information can be used to better diagnose and track prostate cancer. Participants will undergo two PET/MRI scans during two research visits, each of which may last up to 2.5 hours.
Protocol Amendment History 22 amendments
This ClinicalTrials.gov record has been amended 22 times since 2024-11-04; most recent amendment 2026-06-09.
Status change: Suspended → Recruiting 2026-01-05
Status change: Recruiting → Suspended 2025-10-15
Status change: Not Yet Recruiting → Recruiting 2024-11-18
Trial Details
NCT Number NCT06675357
Lead Sponsor University of Wisconsin, Madison
Conditions Prostate Cancer Metastatic Disease, Prostate Cancers
Enrollment 30 participants
Start Date 2026-02-27
Primary Completion 2027-01 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-10